López-Victoria AB, Noffal-Nuño VM

Language: Spanish
References: 17
Page: 21-25
PDF size: 159.14 Kb.

ABSTRACT

Introduction. Inflammatory Bowel Disease (IBD) includes chronic and immune disorders of the gastrointestinal tract. The incidence is 0.08 to 0.5 per 100,000 inhabitants. Despite advances in knowledge, it is still unclear the final trigger of the disease process. However, new developments can help optimize the diagnosis and treatment of these diseases. The diagnosis is established by the clinical history and endoscopic findings and biopsy with its histological confirmation, which is considered as the gold standard. Thus we exposed the concept and utility of serum and fecal biomarkers in order to improve the diagnosis differentiation and patients monitoring. There are available biomarkers as acute phase reactants, e.g. erythrocyte sedimentation rate, C reactive protein, α1-acid glycoprotein (orosomucoid), serum amyloid A and α1-antitrypsin, which its intrinsic characteristic lies on the increasing levels observed. Fecal markers are elevated when by means of an inflammatory process leukocyte migration occurs as calprotectin and lactoferrin. Recently, antibodies are considered new markers against bacteria and fungi cell wall carbohydrates, such as anti-chitobioside (ACCA), anti-laminaribioside (ALCA) anti-mannobioside (AMCA) as well as anti-Saccharomyces cerevisiae (ASCA). Conclusion. There have been great advances in the diagnosis of IBD, which have allowed the development of certain evaluation algorithms which involve the participation of laboratory tests. This development always must stress the improvement of patients’ outcomes.

REFERENCES

1. Yamamoto FJ. Enfermedad inflamatoria intestinal. Rev Gastroenterol Mex 2011; Supl.1 (76): 75-9.

2. Martínez CD, Barrientos RJ, López SA, Guerra AL. Enfermedad inflamatoria intestinal. Revista de Especialidades Médico-Quirúrgicas 2005; 10: 10-20.

3. Quero AL, Argüelles MA, Artieda O. Nuevas herramientas no invasivas en el diagnóstico y seguimiento de la enfermedad inflamatoria intestinal. Utilidad de las tradicionales. Pediat Integral 2007; 11: 133-44.

4. Bunn SK, Bisset WM, Main MJ. Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001; 33: 14-22.

5. Merino OO, Gómez IL, Vitoria CJ, Monterde BV, Sopeña BF, Arroyo VM, et al. ¿Estamos en condiciones de predecir el curso evolutivo de la enfermedad inflamatoria intestinal? En: Alós M, Barreiro M (eds.). Enfermedad inflamatoria intestinal al día. Vol. 8. 3a Ed. Madrid: Adalia; 2009, p. 15-25.

6. Shine B, Berghouse L, Jones JE. C-reactive protein as an aid in the differentiation of functional and inflammatory bowel disorders. Clin Chim Acta 1985; 148: 105-9.

7. Gisbert JP. Marcadores biológicos y pronósticos. En: Gassull MA, Gomollón F (eds.). Enfermedad inflamatoria Intestinal. Vol. 1. 3a Ed. España: Arán; 2007, p.147-63.

8. Peyrin BL, Standaert VA, Branche J, Chamaillard M. IBD serological panels: facts and perspectives. Inflamm Bowel Dis 2007; 13: 1561-6.

9. Li X, Conklin L, Alex P. New serological biomarkers of inflammatory bowel disease. World J Gastroenterol 2008; 14: 5115-24.

10. Joosens S, Rinisch W, Vermiere S, Sendid B, Poulain D, Peeters M, Geboes K, et al. The value of serologic markers indeterminate colitis: a prospective follow-up study. Gastroenterology 2002; 122: 1242-7.

11. Dubinsky MC, Lin Y, Dutridge D, Picornell Y, Landers CJ, Farrior S, Wrobel I, et al. Serum Immune response predict rapid disease progression among children with Crohn’´s disease: immune responses predict disease progression. Am J Gastroenterol 2006; 101: 360-7.

12. Lodes M, Cong Y, Elson C. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Inv 2004; 113: 1296-306.

13. Targan SR, Landers CJ, Yang H, Lodes MS, Cong Y, Papadakis KA, Vasikuauskas E, et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn’s disease. Gastroenterology 2005; 128: 2010-28.

14. Ferrante M, Henckaerts L, Joossens M, Joossens S, Dotan N, Norman GL, Altstock RT, et al. New serological markers in inflammatory bowel disease are associated with complicated disease behavior. Gut 2007, 56: 1394-403.

15. Papp M, Altorjay I, Dotan N, Palatka K, Foldi I, Tumpek J, Sipka S, et al. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort. Am J Gastroenterol 2008; 103: 665-81.

16. Lees C, Satsangi J. Genetics of inflammatory bowel disease: implications for disease pathogenesis and natural history. Expert Rev, Gastroenterol Hepatol 2009; 3: 513-34.

17. Danese S, Fiocchi C. Ulcerative Colitis. N Engl J Med 2011; 365: 1713-25.